stockholmswedish privateequity firm eqt said wednesday that together with its coshareholders it has agreed to sell ellab to novo holdings headquartered in hillerod denmark ellab provides validation and monitoring solutions and services for biotech and pharmaceutical processes eqt said it invested in the company in 2019 and since then ellab has tripled its revenue earnings before interest tax depreciation and amortization and number of employees while experiencing around 20 annual organic revenue growth and completing 15 addon acquisitions the sale to novo holdings is expected to close in the third quarter subject to regulatory approval novo holdings is a holding and investment company responsible for managing the assets and the wealth of the novo nordisk foundation whollyowned by the novo nordisk foundation novo holdings is the controlling shareholder of novo nordisk and novozymes